In vitro evaluation of the hemostatic effectiveness of cryopreserved platelets
BACKGROUND Cryopreserved platelet (CPP) concentrates exhibit a variety of morphologic and functional alterations that may affect the action of CPP with accelerated platelet (PLT) response and clotting. The objective of this study was to compare the in vitro hemostatic effect of CPP with fresh whole...
Saved in:
Published in | Transfusion (Philadelphia, Pa.) Vol. 56; no. 3; pp. 580 - 586 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.03.2016
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | BACKGROUND
Cryopreserved platelet (CPP) concentrates exhibit a variety of morphologic and functional alterations that may affect the action of CPP with accelerated platelet (PLT) response and clotting. The objective of this study was to compare the in vitro hemostatic effect of CPP with fresh whole blood (WB) and standard 5‐day PLT concentrates (PCs).
STUDY DESIGN AND METHODS
WB collected from eight healthy donors was used to prepare fresh WB, PLT‐depleted WB (TPN), and PLT‐restored TPN using CPP (TPN‐CPP) or PC (TPN‐PC). Clot properties were evaluated with thromboelastometry (ROTEM); adhesion and aggregate formation under high shear (Impact‐R); and PLT adhesion, aggregate formation, fibrin formation, and prothrombin activation under medium shear in a perfusion system.
RESULTS
TPN‐CPP had faster clot initiation (ROTEM clot time—TPN‐CPP 115 sec, WB 194 sec, TPN‐PC 161 sec), and CPP contributes to a strong clot with PLT involvement (maximum clot firmness—TPN‐CPP 32 mm, WB 62 mm, TPN‐PC 59 mm). The Impact‐R PLT‐covered area with TPN‐CPP was less than those of WB and PCs, but aggregate size was the same as WB. PLT coverage in perfusion studies was observed with TPN‐CPP, although generally less than both WB and PC. Fibrin was deposited with CPP‐restored samples, but did not exceed the level of WB.
CONCLUSION
CPPs present a phenotype supporting a moderate increase in the rate of clot formation, form stable PLT clots, and do not present a hypercoagulable phenotype during in vitro functional tests. |
---|---|
Bibliography: | Instituto de Salud Carlos III (ISCIII) - No. SAF2011-28214, FIS-PI13/00517, RD12/0042/0016, and PI15/00027 ark:/67375/WNG-65KTX8W2-N U.S. Army Medical Research and Materiel Command - No. W81XWH-08-D-0047 istex:A8A7D33B0938C6E2A80E22887BF6710565868921 Ministerio de Economía y Competitividad ArticleID:TRF13371 European Regional Development Funds This study was supported by the U.S. Army Medical Research and Materiel Command under Contract W81XWH‐08‐D‐0047. The views, opinions, and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of Defense position, policy, or decision unless so designated by other documentation. JC and GE contributed equally to the authorship. This work was partially supported by Grants SAF2011‐28214, FIS‐PI13/00517, RD12/0042/0016, and PI15/00027 from Instituto de Salud Carlos III (ISCIII) and Ministerio de Economía y Competitividad, all contributed with the European Regional Development Funds (FEDER). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0041-1132 1537-2995 |
DOI: | 10.1111/trf.13371 |